Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. / Svane, M S; Jørgensen, Nils B; Bojsen-Møller, K N; Dirksen, C; Nielsen, S.; Kristiansen, V B; Toräng, S; Wewer Albrechtsen, N J; Rehfeld, J F; Hartmann, B; Madsbad, S; Holst, J J.

In: International Journal of Obesity, Vol. 40, 30.08.2016, p. 1699–1706.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Svane, MS, Jørgensen, NB, Bojsen-Møller, KN, Dirksen, C, Nielsen, S, Kristiansen, VB, Toräng, S, Wewer Albrechtsen, NJ, Rehfeld, JF, Hartmann, B, Madsbad, S & Holst, JJ 2016, 'Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery', International Journal of Obesity, vol. 40, pp. 1699–1706. https://doi.org/10.1038/ijo.2016.121

APA

Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., ... Holst, J. J. (2016). Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. International Journal of Obesity, 40, 1699–1706. https://doi.org/10.1038/ijo.2016.121

Vancouver

Svane MS, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Nielsen S, Kristiansen VB et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. International Journal of Obesity. 2016 Aug 30;40:1699–1706. https://doi.org/10.1038/ijo.2016.121

Author

Svane, M S ; Jørgensen, Nils B ; Bojsen-Møller, K N ; Dirksen, C ; Nielsen, S. ; Kristiansen, V B ; Toräng, S ; Wewer Albrechtsen, N J ; Rehfeld, J F ; Hartmann, B ; Madsbad, S ; Holst, J J. / Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. In: International Journal of Obesity. 2016 ; Vol. 40. pp. 1699–1706.

Bibtex

@article{126632088629454c920bd9eeeca9e445,
title = "Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery",
abstract = "BACKGROUND/OBJECTIVES: Exaggerated postprandial secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) may explain appetite reduction and weight loss after Roux-en-Y gastric bypass (RYGB), but causality has not been established. We hypothesized that food intake decreases after surgery through combined actions from GLP-1 and PYY. GLP-1 actions can be blocked using the GLP-1 receptor antagonist Exendin 9-39 (Ex-9), whereas PYY actions can be inhibited by the administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor preventing the formation of PYY3-36.SUBJECTS/METHODS: Appetite-regulating gut hormones and appetite ratings during a standard mixed-meal test and effects on subsequent ad libitum food intake were evaluated in two studies: in study 1, nine patients with type 2 diabetes were examined prospectively before and 3 months after RYGB with and without Ex-9. In study 2, 12 RYGB-operated patients were examined in a randomized, placebo-controlled, crossover design on four experimental days with: (1) placebo, (2) Ex-9, (3) the DPP-4 inhibitor, sitagliptin, to reduce formation of PYY3-36 and (4) Ex-9/sitagliptin combined.RESULTS: In study 1, food intake decreased by 35{\%} following RYGB compared with before surgery. Before surgery, GLP-1 receptor blockage increased food intake but no effect was seen postoperatively, whereas PYY secretion was markedly increased. In study 2, combined GLP-1 receptor blockage and DPP-4 inhibitor mediated lowering of PYY3-36 increased food intake by ~20{\%} in RYGB patients, whereas neither GLP-1 receptor blockage nor DPP-4 inhibition alone affected food intake, perhaps because of concomitant marked increases in the unblocked hormone.CONCLUSIONS: Blockade of actions from only one of the two L-cell hormones, GLP-1 and PYY3-36, resulted in concomitant increased secretion of the other, probably explaining the absent effect on food intake on these experimental days. Combined blockade of GLP-1 and PYY actions increased food intake after RYGB, supporting that these hormones have a role in decreased food intake postoperatively.International Journal of Obesity advance online publication, 30 August 2016; doi:10.1038/ijo.2016.121.",
author = "Svane, {M S} and J{\o}rgensen, {Nils B} and Bojsen-M{\o}ller, {K N} and C Dirksen and S. Nielsen and Kristiansen, {V B} and S Tor{\"a}ng and {Wewer Albrechtsen}, {N J} and Rehfeld, {J F} and B Hartmann and S Madsbad and Holst, {J J}",
year = "2016",
month = "8",
day = "30",
doi = "10.1038/ijo.2016.121",
language = "English",
volume = "40",
pages = "1699–1706",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

AU - Svane, M S

AU - Jørgensen, Nils B

AU - Bojsen-Møller, K N

AU - Dirksen, C

AU - Nielsen, S.

AU - Kristiansen, V B

AU - Toräng, S

AU - Wewer Albrechtsen, N J

AU - Rehfeld, J F

AU - Hartmann, B

AU - Madsbad, S

AU - Holst, J J

PY - 2016/8/30

Y1 - 2016/8/30

N2 - BACKGROUND/OBJECTIVES: Exaggerated postprandial secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) may explain appetite reduction and weight loss after Roux-en-Y gastric bypass (RYGB), but causality has not been established. We hypothesized that food intake decreases after surgery through combined actions from GLP-1 and PYY. GLP-1 actions can be blocked using the GLP-1 receptor antagonist Exendin 9-39 (Ex-9), whereas PYY actions can be inhibited by the administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor preventing the formation of PYY3-36.SUBJECTS/METHODS: Appetite-regulating gut hormones and appetite ratings during a standard mixed-meal test and effects on subsequent ad libitum food intake were evaluated in two studies: in study 1, nine patients with type 2 diabetes were examined prospectively before and 3 months after RYGB with and without Ex-9. In study 2, 12 RYGB-operated patients were examined in a randomized, placebo-controlled, crossover design on four experimental days with: (1) placebo, (2) Ex-9, (3) the DPP-4 inhibitor, sitagliptin, to reduce formation of PYY3-36 and (4) Ex-9/sitagliptin combined.RESULTS: In study 1, food intake decreased by 35% following RYGB compared with before surgery. Before surgery, GLP-1 receptor blockage increased food intake but no effect was seen postoperatively, whereas PYY secretion was markedly increased. In study 2, combined GLP-1 receptor blockage and DPP-4 inhibitor mediated lowering of PYY3-36 increased food intake by ~20% in RYGB patients, whereas neither GLP-1 receptor blockage nor DPP-4 inhibition alone affected food intake, perhaps because of concomitant marked increases in the unblocked hormone.CONCLUSIONS: Blockade of actions from only one of the two L-cell hormones, GLP-1 and PYY3-36, resulted in concomitant increased secretion of the other, probably explaining the absent effect on food intake on these experimental days. Combined blockade of GLP-1 and PYY actions increased food intake after RYGB, supporting that these hormones have a role in decreased food intake postoperatively.International Journal of Obesity advance online publication, 30 August 2016; doi:10.1038/ijo.2016.121.

AB - BACKGROUND/OBJECTIVES: Exaggerated postprandial secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) may explain appetite reduction and weight loss after Roux-en-Y gastric bypass (RYGB), but causality has not been established. We hypothesized that food intake decreases after surgery through combined actions from GLP-1 and PYY. GLP-1 actions can be blocked using the GLP-1 receptor antagonist Exendin 9-39 (Ex-9), whereas PYY actions can be inhibited by the administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor preventing the formation of PYY3-36.SUBJECTS/METHODS: Appetite-regulating gut hormones and appetite ratings during a standard mixed-meal test and effects on subsequent ad libitum food intake were evaluated in two studies: in study 1, nine patients with type 2 diabetes were examined prospectively before and 3 months after RYGB with and without Ex-9. In study 2, 12 RYGB-operated patients were examined in a randomized, placebo-controlled, crossover design on four experimental days with: (1) placebo, (2) Ex-9, (3) the DPP-4 inhibitor, sitagliptin, to reduce formation of PYY3-36 and (4) Ex-9/sitagliptin combined.RESULTS: In study 1, food intake decreased by 35% following RYGB compared with before surgery. Before surgery, GLP-1 receptor blockage increased food intake but no effect was seen postoperatively, whereas PYY secretion was markedly increased. In study 2, combined GLP-1 receptor blockage and DPP-4 inhibitor mediated lowering of PYY3-36 increased food intake by ~20% in RYGB patients, whereas neither GLP-1 receptor blockage nor DPP-4 inhibition alone affected food intake, perhaps because of concomitant marked increases in the unblocked hormone.CONCLUSIONS: Blockade of actions from only one of the two L-cell hormones, GLP-1 and PYY3-36, resulted in concomitant increased secretion of the other, probably explaining the absent effect on food intake on these experimental days. Combined blockade of GLP-1 and PYY actions increased food intake after RYGB, supporting that these hormones have a role in decreased food intake postoperatively.International Journal of Obesity advance online publication, 30 August 2016; doi:10.1038/ijo.2016.121.

U2 - 10.1038/ijo.2016.121

DO - 10.1038/ijo.2016.121

M3 - Journal article

C2 - 27434221

VL - 40

SP - 1699

EP - 1706

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

ER -

ID: 166681574